Table 3.
Multivariable analyses of progression free survival and overall survival in patients st. I–IV with KRAS wild type, KRAS mutated, KRAS G12C, and KRAS non-G12C mutated tumours.
| Variable | PFS | OS | PFS | OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | HR | 95%CI | p | HR | 95%CI | p | |
| Age (years) | 1.01 | (1.00–1.01) | 0.207 | 1.02 | (1.01–1.03) | <0.001 | 1.01 | (1.00–1.01) | 0.214 | 1.02 | (1.01–1.03) | <0.001 |
| Sex | ||||||||||||
| Women | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| Men | 1.09 | (0.93–1.27) | 0.280 | 1.05 | (0.88–1.24) | 0.603 | 1.09 | (0.93–1.27) | 0.283 | 1.05 | (0.89–1.24) | 0.596 |
| Smoking history | ||||||||||||
| Never | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| Former/current | 1.56 | (1.19–2.05) | <0.001 | 1.71 | (1.24–2.33) | 0.001 | 1.56 | (1.19–2.05) | 0.001 | 1.70 | (1.25–2.33) | 0.001 |
| ECOG PS | ||||||||||||
| 0–1 | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| 2 | 2.02 | (1.51–2.71) | <0.001 | 2.90 | (2.15–3.92) | <0.001 | 2.01 | (1.50–2.70) | <0.001 | 2.91 | (2.16–3.94) | <0.001 |
| 3–4 | 4.27 | (2.56–7.14) | <0.001 | 6.51 | (3.83–11.05) | <0.001 | 4.25 | (2.54–7.11) | <0.001 | 6.56 | (3.86–11.14) | <0.001 |
| Stage | ||||||||||||
| I | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| II | 2.11 | (1.58–2.81) | <0.001 | 2.09 | (1.49–2.92) | <0.001 | 2.11 | (1.58–2.82) | <0.001 | 2.08 | (1.49–2.92) | <0.001 |
| III | 3.02 | (2.28–3.99) | <0.001 | 2.67 | (1.92–3.71) | <0.001 | 3.02 | (2.28–3.99) | <0.001 | 2.67 | (1.92–3.72) | <0.001 |
| IV | 4.61 | (3.18–6.67) | <0.001 | 4.34 | (2.91–6.47) | <0.001 | 4.61 | (3.19–6.68) | <0.001 | 4.34 | (2.91–6.47) | <0.001 |
| Surgery | ||||||||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| Yes | 0.36 | (0.25–0.52) | <0.001 | 0.25 | (0.11–0.37) | <0.001 | 0.36 | (0.25–0.52) | <0.001 | 0.25 | (0.17–0.37) | <0.001 |
| Curative RT +/− CT first line | ||||||||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| Yes | 0.74 | (0.51–1.09) | 0.127 | 0.47 | (0.31–0.73) | <0.001 | 0.74 | (0.51–1.09) | 0.130 | 0.47 | (0.31–0.73) | 0.001 |
| Palliative CT and/or RT first line | ||||||||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| Yes | 1.49 | (1.19–1.88) | <0.001 | 1.16 | (0.90–1.48) | 0.250 | 1.49 | (1.18–1.87) | 0.001 | 1.16 | (0.91–1.48) | 0.236 |
| History of TKI (any line) | ||||||||||||
| No | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | ||||||||
| Yes | 0.78 | (0.58–1.03) | 0.081 | 0.65 | (0.47–0.90) | 0.009 | 0.78 | (0.58–1.03) | 0.081 | 0.65 | (0.47–0.90) | 0.009 |
| KRAS status | ||||||||||||
| Wild type | 1 (ref) | 1 (ref) | - | - | - | - | - | - | ||||
| Mutated | 0.98 | (0.83–1.15) | 0.801 | 0.96 | (0.80–1.15) | 0.678 | - | - | - | - | - | - |
| KRAS G12C status | ||||||||||||
| Wild type | - | - | - | - | - | - | 1 (ref) | 1 (ref) | ||||
| G12C | - | - | - | - | - | - | 0.96 | (0.77–1.19) | 0.691 | 1.00 | (0.79–1.28) | 0.972 |
| KRAS non-G12C | - | - | - | - | - | - | 1.00 | (0.82–1.21) | 0.977 | 0.93 | (0.75–1.16) | 0.530 |
Abbreviations: PFS, progression free survival; OS, overall survival; ref reference; ECOG PS, Eastern Cooperative Oncology Group performance status; CT, chemotherapy; RT, radiotherapy; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor.